Percutaneous radiofrequency ablation as first-line treatment for small hepatocellular carcinoma: Results and prognostic factors on long-term follow up

e15573 Background: The role of anti-epidermal growth factor receptor (EGFR) targeting treatment in esophageal squamous cell carcinoma (ESCC) is still uncertain. We conducted a prospective phase 2 study of paclitaxel, cisplatin, and nimotuzumab (TPN) as first-line treatment in unresectable or metastatic ESCC (NCT01336049). The objective response rate was 51.8%. Here we reported long-term follow-up results of that initial trial. Methods: 59 patients were enrolled from Mar 2011 to Apr 2013 and treated with the TPN regimen (nimotuzumab 200mg weekly, paclitaxel 175mg/m2 on day1, and cisplatin 30mg/m2 on day1 and 2, repeat every 3 weeks for total six cycles). Patients were allowed to receive sequential radiotherapy in case of local-regional disease or controlling symptom. Results: 56 of 59 patients were eligible for evaluation. After a median follow-up of 32.2months, the median progression-free survival (PFS) and overall survival (OS) were 18.1±4.2 months (95% Confidence: 9.8-26.4) and 26.2±10.0 months (95% Confidence: 6.6-45.8) in 29 patients with unresectable local-regional disease, while those were 6.6±0.4 months (95% Confidence: 5.8-7.5) and 11.5±3.7 months (95% Confidence: 4.2-18.8) respectively in 27 patients with metastatic disease. Patients of male, with multiple lymph node station metastasis, visceral metastasis, no response to TPN treatment, and without radiotherapy had worse OS. Even in some patients with multiple stations lymph node metastasis or recurrent disease of local-regional lymph node metastasis, TPN with sequential radiation seemed could bring longer survival time. But multivariate cox-regression analysis only confirmed that the TPN treatment was associations with OS. Compared with those of complete and partial response, patients of stable disease and progression had poor OS (HR = 2.32, 95% CI: 1.03-5.05, p = 0.03). Conclusions: the combination of nimotuzumab, paclitaxel, and cisplatin is effective as first-line treatment for patients with unresectable and metastatic ESCC, especially those with sequential radiotherapy. Clinical trial information: NCT01336049.

Download Full-text

Arsenic Trioxide as First Line Therapy for New Case of APL, Results and Long Term Follow up.

Blood ◽

10.1182/blood.v114.22.1023.1023 ◽

2009 ◽

Vol 114 (22) ◽

pp. 1023-1023

Author(s):

Ardeshir Ghavamzadeh ◽

Kamran Alimoghaddam ◽

Seyed Hamidolah Ghaffari ◽

Shahrbano Rostami ◽

Mohamad Jahani ◽

...

Keyword(s):

Arsenic Trioxide ◽

Early Mortality ◽

Line Treatment ◽

Rt Pcr ◽

Treatment Needs ◽

First Line ◽

Long Term Follow Up ◽

First Line Treatment

Abstract Abstract 1023 Poster Board I-45 Arsenic Trioxide approved for treatment of APL patients who relapsed after first line treatment failure by ATRA and chemotherapy. Its efficacy as first line treatment studied in at least three trials (including our center reports) previously. Here we are studying its efficacy, safety and long term follow up of new cases of APLwho treated by Arsenic trioxide without ATRA and/or Chemotherapy. Material and methods: between 1999 and 2009 we treated 190 new cases of APL by Arsenic Trioxide ( 0.15 mg/kg/day till CR ). Presence of t(15,17) confirmed in all cases by cytogenetic study and/or RT-PCR. In patients who achieved to CR we applied 4 more courses of daily ATO with the same dose for 28 days. Patients followed every 3 months by physical exam, hemogram and RT-PCR on peripheral blood for detection of relapse. Results: Median age of our patients was 29 years. Remission rate was 84.7% and median time to achieve to CR was 30 days. Median follow up was 37 months (maximum105 months) and for patients in remission, DFS was 73.4%. Also chance of 3 and 5 years DFS and OS were 71.3%, 83% and 67.6%, 72% respectively. Also Although early mortality was higher in patients with WBC more than 10000 at presentation, we couldn't find any significant correlation between DFS or OS and at presentation WBC count. Conclusion: Arsenic trioxide is effective as first line treatment of new cases of APL. Its long term results is comparable with conventional treatment of APL. optimization of treatment needs better supportive care to reduce early mortality due to APL differentiation syndrome and hemorrhagic episodes. Disclosures: No relevant conflicts of interest to declare.

Download Full-text

Bariatric Surgery as a First Line Treatment of Type 2 Diabetes in Patients with Obesity Class I and II: 89% Diabetes Remission in Long-term Follow-up

Surgery for Obesity and Related Diseases ◽

10.1016/j.soard.2017.09.292 ◽

2017 ◽

Vol 13 (10) ◽

pp. S132

Author(s):

Ali Aminian ◽

Suriya Punchai ◽

Zubaidah Nor Hanipah ◽

Philip Schauer ◽

Stacy Brethauer

Keyword(s):

Bariatric Surgery ◽

Diabetes Remission ◽

Line Treatment ◽

First Line ◽

Obesity Class ◽

Long Term Follow Up ◽

First Line Treatment

Download Full-text

Long-Term Follow-Up of Patients With Newly Diagnosed Follicular Lymphoma in the Prerituximab Era: Effect of Response Quality on Survival—A Study From the Groupe d'Etude des Lymphomes de l'Adulte

Journal of Clinical Oncology ◽

10.1200/jco.2009.22.7819 ◽

2010 ◽

Vol 28 (5) ◽

pp. 822-829 ◽

Cited By ~ 54

Author(s):

Emmanuel Bachy ◽

Pauline Brice ◽

Richard Delarue ◽

Nicole Brousse ◽

Corinne Haioun ◽

...

Keyword(s):

Follicular Lymphoma ◽

Tumor Burden ◽

Line Treatment ◽

Newly Diagnosed ◽

First Line ◽

Response Quality ◽

Long Term Follow Up ◽

First Line Treatment

Purpose First-line treatment for patients with newly diagnosed follicular lymphoma (FL) still remains debated, even in the rituximab-based combination therapy era. Few studies have addressed the question whether complete remission (CR) translates into better survival. The aim of this study was to assess the long-term follow-up of prospectively treated patients with FL and the potential correlation between response quality to first-line treatment and overall survival (OS). Patients and Methods Data from 536 patients with FL with low (n = 193) or high (n = 343) tumor burden enrolled from October 1986 to May 1995 in the French and Belgian GELF86 studies were analyzed. Data from these trials have been previously reported for low–tumor burden and high–tumor burden patients. Results Median follow-up was 14.9 years, and median OS was 9.8 years. Treated patients who achieved a complete response (CR; n = 194; 45%) had a significant longer OS than those only reaching a partial response (PR; n = 168; 39%) throughout treatment (hazard ratio [HR], 0.55; 95% CI, 0.42 to 0.72; P < .001) in an univariate time-dependent Cox model. Similar findings were found when response to treatment (CR v PR) was adjusted for potentially confounding factors in a multivariate model (HR, 0.53; 95% CI, 0.38 to 0.73; P < .001). Conclusion These data provide a long follow-up of these patients' cohorts and indicate that a better response to first-line treatment translates into an improved survival for patients with FL. Therefore, response-adapted therapy aiming to achieve a CR should be considered as first-line treatment.

Download Full-text